Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANRO
#2247
Alto Neuroscience, Inc. Common Stock
35.1
3
USD
-0.03%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-3.01%
Monthly Change
+32.52%
6 month change
+81.46%
Year Change
+854.62%
Previous Close
36.2
2
Open
35.2
8
Low
35.0
0
High
35.4
0
Volume
75
Markets
US Stock Market
Healthcare
Biotechnology
ANRO
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2024
2025
Current
Key stats
Total common shares outstanding
27.07 M
31.95 M
39.24 M
Valuation ratios
Enterprise value
-43.46 M
408.32 M
1.27 B
Price to earnings ratio
-1.69
-8.13
-15.72
Price to sales ratio
2 001.28
-613.58
-8 525.25
Price to cash flow ratio
2.19
-9.92
-18.63
Price to book ratio
0.69
3.4
1.75
Enterprise value to EBITDA ratio
0.64
-6.14
-14.5
Profitability ratios
Return on assets %
-0.35
-0.34
-0.11
Return on equity %
-0.41
-0.42
-0.13
Return on invested capital %
-3 344.79
-3 513.18
—
Gross margin %
100
100
—
Operating margin %
131.94 K
7 928.79
—
EBITDA margin %
131.08 K
7 949.82
—
Net margin %
118.14 K
7 555.32
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
16.92
15.69
14.85
Inventory turnover
—
—
—
Asset turnover
-0
-0
0
Solvency ratios
Debt to assets ratio
0.06
0.09
0.06
Debt to equity ratio
0.07
0.11
0.07
Long term debt to total assets ratio
0.06
0.01
0.01
Long term debt to total equity ratio
0.07
0.01
0.01
Per share metrics
Operating cash flow per share
-1.93
-1.79
-2.05
EBIT per share
-2.79
-2.33
-2.65
EBITDA per share
-2.77
-2.31
-2.63
Total debt per share
0.42
0.56
0.38
Cash per share
6.84
6.12
5.69
Net current asset value per share
6.88
6.16
5.78
Tangible book value per share
6.16
5.24
5.12
Working capital per share
6.48
5.77
5.39
Book value per share
6.16
5.24
5.12
News
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO)
Stocks Recover on Hopes Strait of Hormuz Could Soon Reopen
Stocks Pare Losses on Hormuz Report
Stocks Sink as President Trump Signals Iran War Will Drag On
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
Jefferies raises Alto Neuroscience stock price target on pipeline
Alto Neuroscience raises $120M to fund depression drug trial
Alto Neuroscience completes enrollment in schizophrenia drug trial
Alto Neuroscience receives patent for depression treatment method
Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating
Tesla and ServiceNow among market cap stock movers on Monday
Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 (NYSE:ANRO)